JP2018528213A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528213A5 JP2018528213A5 JP2018512274A JP2018512274A JP2018528213A5 JP 2018528213 A5 JP2018528213 A5 JP 2018528213A5 JP 2018512274 A JP2018512274 A JP 2018512274A JP 2018512274 A JP2018512274 A JP 2018512274A JP 2018528213 A5 JP2018528213 A5 JP 2018528213A5
- Authority
- JP
- Japan
- Prior art keywords
- igfr
- seq
- antagonist
- receptor
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022179426A JP7807359B2 (ja) | 2015-09-07 | 2022-11-09 | 新規なｉｇｆｒ様レセプター及びその使用 |
| JP2025132452A JP2025166096A (ja) | 2015-09-07 | 2025-08-07 | 新規なｉｇｆｒ様レセプター及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| LU92818 | 2015-09-07 | ||
| LU92818 | 2015-09-07 | ||
| PCT/EP2016/071126 WO2017042242A1 (en) | 2015-09-07 | 2016-09-07 | Novel igfr-like receptor and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179426A Division JP7807359B2 (ja) | 2015-09-07 | 2022-11-09 | 新規なｉｇｆｒ様レセプター及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528213A JP2018528213A (ja) | 2018-09-27 |
| JP2018528213A5 true JP2018528213A5 (enExample) | 2019-09-19 |
| JP7175760B2 JP7175760B2 (ja) | 2022-11-21 |
Family
ID=54337321
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018512274A Active JP7175760B2 (ja) | 2015-09-07 | 2016-09-07 | 新規なｉｇｆｒ様レセプター及びその使用 |
| JP2022179426A Active JP7807359B2 (ja) | 2015-09-07 | 2022-11-09 | 新規なｉｇｆｒ様レセプター及びその使用 |
| JP2025132452A Withdrawn JP2025166096A (ja) | 2015-09-07 | 2025-08-07 | 新規なｉｇｆｒ様レセプター及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022179426A Active JP7807359B2 (ja) | 2015-09-07 | 2022-11-09 | 新規なｉｇｆｒ様レセプター及びその使用 |
| JP2025132452A Withdrawn JP2025166096A (ja) | 2015-09-07 | 2025-08-07 | 新規なｉｇｆｒ様レセプター及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190248905A1 (enExample) |
| EP (2) | EP3896080A1 (enExample) |
| JP (3) | JP7175760B2 (enExample) |
| CN (1) | CN108026160A (enExample) |
| DK (1) | DK3347376T3 (enExample) |
| ES (1) | ES2862175T3 (enExample) |
| PL (1) | PL3347376T3 (enExample) |
| WO (1) | WO2017042242A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112469826B (zh) * | 2018-04-27 | 2024-02-09 | (株)爱恩德生物 | 通过磁珠附着至细胞进行的基于磁性的生物淘选方法 |
| CN113773400B (zh) * | 2020-06-09 | 2023-08-18 | 宁波鲲鹏生物科技有限公司 | 一种门冬胰岛素衍生物及其应用 |
| CA3226102A1 (en) * | 2021-07-23 | 2023-01-26 | Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Igfr-l1 antibodies and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US20020137890A1 (en) | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| WO2007005987A2 (en) * | 2005-07-06 | 2007-01-11 | Applera Corporation | Methods and compositions for treating diseases targeting maba1 |
| US20110229480A1 (en) * | 2008-09-04 | 2011-09-22 | Oxford Biotherapeutics Ltd | Pta072 protein |
| WO2013151663A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9880179B2 (en) | 2013-02-05 | 2018-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Method for selecting agents that bind to transmembrane receptors in a conformationally selective manner |
-
2016
- 2016-09-07 DK DK16777913.1T patent/DK3347376T3/da active
- 2016-09-07 PL PL16777913T patent/PL3347376T3/pl unknown
- 2016-09-07 ES ES16777913T patent/ES2862175T3/es active Active
- 2016-09-07 JP JP2018512274A patent/JP7175760B2/ja active Active
- 2016-09-07 EP EP21150160.6A patent/EP3896080A1/en active Pending
- 2016-09-07 US US15/757,568 patent/US20190248905A1/en not_active Abandoned
- 2016-09-07 CN CN201680051667.1A patent/CN108026160A/zh active Pending
- 2016-09-07 EP EP16777913.1A patent/EP3347376B1/en active Active
- 2016-09-07 WO PCT/EP2016/071126 patent/WO2017042242A1/en not_active Ceased
-
2022
- 2022-11-09 JP JP2022179426A patent/JP7807359B2/ja active Active
-
2025
- 2025-08-07 JP JP2025132452A patent/JP2025166096A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nemet et al. | A cardiovascular disease-linked gut microbial metabolite acts via adrenergic receptors | |
| Gusev et al. | The pathogenesis of end-stage renal disease from the standpoint of the theory of general pathological processes of inflammation | |
| Beunders et al. | Proenkephalin (PENK) as a novel biomarker for kidney function | |
| Mitra et al. | Role of α-crystallin B as a regulatory switch in modulating cardiomyocyte apoptosis by mitochondria or endoplasmic reticulum during cardiac hypertrophy and myocardial infarction | |
| Huang et al. | Evaluation of biomarkers for in vitro prediction of drug‐induced nephrotoxicity: comparison of HK‐2, immortalized human proximal tubule epithelial, and primary cultures of human proximal tubular cells | |
| Odemis et al. | The presumed atypical chemokine receptor CXCR7 signals through G (i/o) proteins in primary rodent astrocytes and human glioma cells. | |
| US9945870B2 (en) | Methods for determining responsiveness to an anti-CD47 agent | |
| Hattori et al. | A case of IgG4-related hypophysitis without pituitary insufficiency. | |
| EP4033248B1 (en) | System and method for analysis of mx1 and crp in blood | |
| Youn et al. | Increased frequency of CD4+ CD57+ senescent T cells in patients with newly diagnosed acute heart failure: exploring new pathogenic mechanisms with clinical relevance | |
| Zhou et al. | Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets | |
| Kemp et al. | Prevalence and clinical associations of calcium-sensing receptor and NALP5 autoantibodies in Finnish APECED patients. | |
| Miller et al. | Signaling pathways that regulate basal ABC transporter activity at the blood-brain barrier | |
| Kärner et al. | IL‐6‐specific autoantibodies among APECED and thymoma patients | |
| Stockwin et al. | Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma | |
| Novick | IL-18 and IL-18BP: A unique dyad in health and disease | |
| JP2010536043A5 (enExample) | ||
| Morita et al. | Highly selective and sensitive detection of β-agonists using a surface plasmon resonance sensor based on an alkanethiol monolayer functionalized on a Au surface | |
| Lewis et al. | Bidirectional counterregulation of human lung mast cell and airway smooth muscle β2 adrenoceptors | |
| Van Der Velde et al. | Biomarkers for risk prediction in acute decompensated heart failure | |
| JP2015500797A5 (enExample) | ||
| Wu et al. | MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer | |
| Gluschke et al. | Autoimmunity to sphingosine-1-phosphate-receptors in systemic sclerosis and pulmonary arterial hypertension | |
| Philippe et al. | Molecular effects of auto-antibodies on angiotensin II type 1 receptor signaling and cell proliferation | |
| Flaherty III et al. | Chronic UCN2 treatment desensitizes CRHR2 and improves insulin sensitivity |